

FOR IMMEDIATE RELEASE

From PhenoTech, Inc.

MEDIA CONTACT: Guy Maestre, 610-761-7311

PhenoTech Announces New Appointment to Board of Directors

PHILADELPHIA, May 11, 2006 -- PhenoTech, Inc., a privately held biopharmaceutical company developing novel diagnostic and therapeutic monoclonal antibodies (mAbs) announced today the appointment of Peter Wilding, Ph.D., F.R.C. Path. to its Board of Directors.

Dr. Wilding is a recognized expert in the field of clinical chemistry and the development of microfluidic microchip technology. He has lectured on these topics throughout the world and has received several awards from national associations for his contribution to the field of clinical chemistry. Dr. Wilding is Professor Emeritus in the Department of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine. Until 2003 he was Director of Clinical Chemistry at the University of Pennsylvania Medical Center for over 15 years. Prior to this, Dr. Wilding spent 9 years in the diagnostics industry as a Vice President with Technicon and SmithKline Beckman. In 1990 he co-founded the ChemCore Corporation which subsequently merged to form Caliper Technologies. From 1995 to 2003 he played key roles, including President, CEO and Director for Aviva Biosciences Corporation.

“We are delighted to welcome Peter to our Board of Directors” said Guy Maestre, President, CEO and Chairman of PhenoTech. “Dr. Wilding brings to PhenoTech his strong academic and business experience in the field of diagnostics and his leadership skills in the creation, funding and management of early-stage biotech companies. We are looking forward to working closely with him to establish the strategic direction for our company”.

“I am delighted to be engaged in the development of PhenoTech’s unique technology which, I believe, will play a significant role in changing the nature and scope of blood typing and transfusion medicine” added Peter Wilding.

Dr. Wilding graduated from the University of Birmingham, UK with an honors degree in Medical Biochemistry in 1961 and with a Ph.D. from the Department of Medicine in the same university in 1965. From 1965-1977 he held faculty appointments at the University of Southern California School of Medicine and the University of Birmingham, UK.

Phenotech is employing its proprietary phage display mAb production technology to develop an important new generation of blood typing reagents, which should support an improved standard of care for patients and physicians and significantly impact the economics of blood typing. This approach will provide large amounts of phage-displayed reagents which are not dependent on rare human supplies. Phage display will allow the development of reagents which cannot be obtained by current hybridoma methodology. Thanks to their superior sensitivity over currently available products, they should also better support automation technology. Furthermore, by exploiting the naturally-occurring presence of unique DNA sequences within the phage reagents, they will allow simultaneous typing (multiplexing) of the various blood cell antigens in a single well assay by our “phenotyping-by-reagent-genotyping” approach. This should provide a faster, easier and more comprehensive alternative to current 50 year old reagent technology.

About PhenoTech, Inc.

PhenoTech, Inc., based in Philadelphia, PA, is a privately held biopharmaceutical company dedicated to the discovery, development and commercialization of innovative monoclonal antibodies (mAbs) to be used in blood diagnostic and blood therapeutic applications. PhenoTech has developed a set of novel molecular technologies based on magnetic cell separation and phage

display mAb discovery and production for rapidly creating and screening innovative self-replicating mAbs. PhenoTech is applying its proprietary technology to the development of innovative blood cell typing reagents and of therapeutic drugs targeting various hematologic and cardiovascular disorders.

For more information regarding PhenoTech, Inc. visit www.phenotech.com or e-mail the company at info@phenotech.com.

###

The statements in this document, which are not historical facts, are forward looking statements based on current expectations of future events that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, manufacturing, commercialization, economic conditions, the impact of competitive or generic products, product liability, the impact of legislative and regulatory compliance and obtaining approvals, and patent, and other risks and uncertainties. Forward looking statements often contain such words as estimate, anticipate, intend, plan, expect or might, could or should. Research findings are not always supportable by evidence obtained from subsequent development trials and the Company can make no assurances that the development trials will yield positive results. Final review decisions made by the FDA and other regulatory agencies concerning development trial results are unpredictable and outside the influence and/or control of the Company.